The role of HLA-DQ2.2 genotype for patients with celiacia

Abstract

The aim of this study was to observe the role of the genotype DQ 2.2 in patients with celiac disease (CD): serological and morphological features of celiac disease in patients with the DQ2.2 genotype Materials and methods: We examined 47 patients with СD, diagnosed according to ESPHGAN criteria. All participants were tested for antibodies to tissue transglutaminase-2 (TTG) and deamidated gliadin peptides, morphometric examination of biopsy specimens of duodenal mucosa and genotyping were carried out. Based on the results of genotyping, patients were divided into 2 groups: group 1 comprised 18 patients with the genotype DQ2.2; group of 2-29 patients with other genotypes of CD. Results: an increase of anti-TTG antibodies was observed in all patients in group 1. Moreover, a moderate increase in group 1 was 55.6%, and in the 2nd group, 27.6% (p = 0.07). A significant increase of anti-TTG in group 1-44.4%, in the 2 group - 3.4% (p = 0.001). In addition, the morphological changes of the duodenal mucosa corresponding to the level of Marsh 3b were more often observed in group 1-27.8% than in 2-0% (p = 0.006). Morphometric parameters of duodenal mucosa in group 1 reveal more severe atrophic changes. Conclusion: it is expected that the detection of the genotype DQ2.2 can serve as a predictor of severe serological (a significant increase of anti-TTG antibodies level) and morphological changes in CD.